Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
NV

OTC · NVZMY

Novozymes A/S

Basic Materials · Chemicals - Specialty

$65.64

Up+$1.45 (+2.26%)

Updated Aug 16, 2026, 9:53 PM

SID Score

4.9/10

Composite research score

Smart Money

46/100

Neutral

Market cap
28.82B
P/E ratio
115.06
Dividend yield
1.47%
52-week range
— – —
Volume
4.09K
Avg. volume
36.05K

Price performance

NVZMY price history

1M range · 0 trading sessions · Daily adjusted prices

NVZMY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest NVZMY news

The latest Smart Investors Daily articles mentioning NVZMY.

Stock researchCompany · Overview

NVZMY research

Overview

Company profile and research snapshot.

Company profile

NOVONESIS B UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NVZMY recent ratings
DateFirmRatingTarget
Jul 13, 2026JYSKE BANKBuy—
Jul 8, 2026ROTHSCHILD & CO REDBURNBuy—
Jun 30, 2026JEFFERIESBuy—
Jun 24, 2026BAADER EUROPE / ALPHAVALUEBuy—
May 4, 2026BERENBERGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 26, 2026

Invitation to the 2026 Annual General Meeting

The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis

Yahoo · Feb 25, 2026

Novonesis delivered strong organic sales growth of 7% in 2025

COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong perfor

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By